TITLE:
Predictive Significance of IL-17A Serum Levels during Chemotherapy in Senegalese Women with Cervical Cancer
AUTHORS:
Folly Mawulolo Gaba, Babacar Mbengue, Maimouna Diop, Doudou Diouf, Sidy Ka, Doudou Georges Massar Niang, Ramatoulaye Ndiaye, Ibrahima Mounkeila Seydou, Jean Pascal Demba Diop, Moustapha Mbow, Rokhaya Ndiaye Diallo, Maguette Sylla Niang, Mbacké Sembene, Ahmadou Dem, Alioune Dieye
KEYWORDS:
Cervical Cancer, Chemotherapy, Interleukin 17A
JOURNAL NAME:
Open Journal of Immunology,
Vol.9 No.4,
December
30,
2019
ABSTRACT: Background and Objectives: Cervical cancer is a leading cause of cancer death in female populations. It is a virally induced carcinoma resulting from sexually transmitted high risk Human Papillomavirus infections (e.g. HPV-16, HPV-18). Previous studies have shown associations between IL-17A levels in cancer micro-environments and metastasis of tumor cells. In Africa, chemotherapy (CT) is the standard first-line treatment for cervical cancer and the prognosis remains poor for metastatic and recurrent cases. The impact of CT as a treatment option is still unclear. We investigated the prognostic relevance of IL-17A profiles in Cervical cancer patients (CP) patients treated with cisplatin in combination with 5-fluouracil (5FU) for three cycles. Methods: The study included 57 CP and 59 women with no history of malignancy as healthy controls (HC). IL-17A plasma levels were evaluated by ELISA. For each CP, three blood samples were collected at three-week intervals before initiation of the chemotherapy protocol. Results: Before chemotherapy CP showed higher serum levels of IL-17A compared to HCs (p = 0.035). No relation was detected between age and IL-17A levels. We observed a significant increase in serum IL-17A during treatment of the CP group (p Conclusion: Our results suggest that high serum levels of IL-17A are associated with poor responses to classical chemotherapy. However, considering these results to design CC biomarkers, we need further investigations particularly about the relevant prognostic indicator following chemotherapy.